PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 2, 2015JAMA Oncology311 citationsOpen Access

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

NKNeha KordeMRMark RoschewskiAZAdriana Zingone

Key Points

Key points are not available for this paper at this time.

Abstract

Carfilzomib-lenalidomide-dexamethasone therapy is tolerable and demonstrates high rates of MRD negativity in NDMM, translating into longer progression-free survival in patients achieving MRD negativity. Carfilzomib-lenalidomide-dexamethasone therapy also demonstrates efficacy in high-risk SMM.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Korde et al. (2015) studied this question.

synapsesocial.com/papers/69dd61830644c7b49d40d47ahttps://doi.org/10.1001/jamaoncol.2015.2010
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA‐NCI roundtable symposium2014 · 56 citations
  2. 2Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity2013 · 92 citations
  3. 3Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop2012 · 54 citations
  4. 4The genetic architecture of multiple myeloma2012 · 929 citations
  5. 5Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma2007 · 434 citations